本文已被:浏览 244次 下载 188次
Received:June 15, 2023 Published Online:March 20, 2024
Received:June 15, 2023 Published Online:March 20, 2024
中文摘要: 随着对溃疡性结肠炎管理模式发生转变,治疗目标已从单纯的症状缓解转变为症状与内镜双重缓解。近年来,随着对炎症性肠病发病机制的深入研究,已从基因组学、蛋白质组学、微生物组学、转录组学、代谢组学等方面鉴定出诸多非侵入性生物标志物,且已应用于临床诊断、疗效评估和预后预测等,本文就已经应用于临床的以及新型的、潜在的生物标志物进行综述。
Abstract:With the paradigm shift in the management of ulcerative colitis, the treatment goal has shifted from symptomatic relief alone to dual relief of symptomatic and endoscopic. In recent years, with the in-depth study of the pathogenesis of inflammatory bowel disease, many non-invasive biomarkers have been identified from genomics, proteomics, microbiomics, transcriptomics, metabolomics, etc. These biomarkers have been applied to the diagnosis, efficacy evaluation and prognosis prediction of ulcerative colitis. This article reviews the biomarkers that have been applied in clinical practice, as well as novel and potential ones.
keywords: Ulcerative colitis MicroRNA Infliximab Toll-like receptor Tumor necrosis factor-alpha Biomarker Proteomics Microbiomics Metabolomics Feacal calportectin Inflammatory bowel disease Antibody
文章编号: 中图分类号:R574.6 文献标志码:A
基金项目:
引用文本: